Application of vincristine and cisplatin combined with intensity-modulated radiation therapy in the treatment of patients with advanced cervical cancer

Objective: To investigate the effect of vincristine and cisplatin combined with intensity-modulated radiation therapy (IMRT) on the treatment of patients with advanced cervical cancer and its influence on adverse reactions. Methods: In this retrospective clinical trial, 90 patients with advanced cervical cancer admitted to our hospital from January 2019 to January 2020 were collected as research subjects and were divided into two groups according to different treatment methods. The control group received IMRT, and the experimental group was treated with a triple therapy of vincristine, cisplatin, and IMRT. The clinical efficacy, incidence of adverse reactions, immune function indexes, serum indexes, and 3-year survival were compared between the two groups. The Generic Quality of Life Inventory-74 (GQOLI-74) questionnaire was used to assess the quality of life, and the Karnofsky Performance Scale (KPS) was used to evaluate the health status. Results: The experimental group exhibited a significantly higher total clinical treatment efficacy in comparison with the control group (P 0.05). Patients in the experimental group experienced fewer adverse reactions and better immune indexes as compared to those in the control group (all P 0.05). The serum indexes of the experimental group were significantly lower than those of the control group (P<0.05). Significantly higher GQOLI-74 scores and KPS scores were obtained in the experimental group than the control group after treatment (all P<0.05). The 3-year overall survival rate of the experimental group was significantly higher than that of the control group (P<0.05). Conclusion: Vincristine and cisplatin combined with IMRT for patients with advanced cervical cancer can effectively optimize the clinical indicators of patients and improve their quality of life, with a high safety.